阿戈美拉汀联合舒肝解郁胶囊治疗成人复发性抑郁障碍的临床研究

Clinical study of agomelatine combined with Shugan Jieyu capsule in the treatment of adult recurrent depressive disorder

目的探究阿戈美拉汀联合舒肝解郁胶囊治疗成人复发性抑郁障碍的临床研究。方法选取2021年7—12月赣州市第三人民医院收治的66例复发性抑郁障碍患者作为研究对象,根据随机数字表法分为对照组与研究组,每组33例。对照组给予阿戈美拉汀治疗,研究组在对照组基础上联合应用舒肝解郁胶囊治疗,比较两组临床疗效、汉密尔顿抑郁量表(HAMD)评分、药物不良反应量表(TESS)评分、药物起效时间、匹兹堡睡眠质量指数(PSQI)评分及不良反应发生率。结果研究组治疗总有效率为93.94%,高于对照组的69.70%,差异有统计学意义(P<0.05)。两组HAMD评分组间、时间、交互比较差异有统计学意义(P<0.05)。组内比较:治疗1、2、4、6周,两组HAMD评分均低于前一时间点,差异有统计学意义(P<0.05)。组间比较:治疗前、治疗1周后,两组HAMD评分比较差异无统计学意义;治疗2、4、6周后,研究组HAMD评分均低于对照组,差异有统计学意义(P<0.05)。两组TESS评分时间比较差异有统计学意义(P<0.05);两组TESS评分组间、交互比较差异无统计学意义。组内比较:治疗2、4、6周,两组TESS评分均低于前一时间点,差异有统计学意义(P<0.05)。组间比较:治疗1、2、4及6周后,两组TESS评分比较差异无统计学意义。研究组药物起效时间短于对照组,差异有统计学意(P<0.05);治疗6周后,两组PSQI评分均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论阿戈美拉汀联合舒肝解郁胶囊治疗复发性抑郁障碍患者疗效确切,可缓解患者抑郁情绪,改善患者睡眠质量,且药物时间快,安全性良好,可临床推广应用。

Objective To investigate the clinical study of agomelatine combined with Shugan Jieyu capsule in the treatment of adult recurrent de-pressive disorder.Methods A total of 66 patients with recurrent depressive disorder were admitted to the Third People's Hospital of Ganzhou from July to December 2021 were selected as the study subjects,and they were divided into the control group and the study group according to the random number table method,with 33 cases in each group.The control group was treated with agomelatine,while the study group was treated with agomela-tine combined with Shugan Jieyu capsule on basis of the control group,the clinical efficacy,Hamilton depression scale(HAMD)score,treatment emergent symptom scale(TESS)score,drug onset time,pittsburgh sleep quality index(PSQI)score and incidence of adverse reactions were com-pared between the two groups.Results The total effective rate in the study group was 93.94%,which was higher than 69.70%in the control group,and the difference was statistically significant(P<0.05).There were significant differences in HAMD between the two groups of group,time points and interaction(P<0.05).Comparison within the group:after 1,2,4 and 6 weeks of treatment,HAMD scores of the two groups were lower than the previous time point,and the differences were statistically significant(P<0.05).Comparison between groups:Before and after 1 week of treatment,there was no significant difference in HAMD scores between the two groups;after 2,4 and 6 weeks of treatment,HAMD scores in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was significant difference in TESS scores between the two groups of time points(P<0.05).There was no significant difference in TESS scores between the two groups of group and in-teraction.Comparison within the group:after 2,4,and 6 weeks of treatment,TESS scores in both groups were lower than at the previous time point,and the differences were statistically significant(P<0.05).Comparison between groups:after 1,2,4 and 6 weeks of treatment,there were no statisti-cally significant differences in TESS scores between the two groups.The drug onset time in the study group was shorter than that in the control group,and the difference was statistically significant(P<0.05).After 6 weeks of treatment,the PSQI scores of the two groups were lower than be-fore treatment,and the study group was lower than the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Agomelatine combined with Shugan Jieyu capsule is effective in the treatment of patients with recurrent depressive disorder,it can relieve depression and improve sleep quality,and the drugs take effect quickly and are safe,which is worthy of clinical promotion and application.